NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News $76.37 -1.18 (-1.52%) As of 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsBuy This Stock About SPDR S&P Biotech ETF (NYSEARCA:XBI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SPDR S&P Biotech ETF alerts:Sign Up Key Stats Today's Range$75.90▼$78.4650-Day Range$69.80▼$88.8252-Week Range$66.66▼$105.47Volume13.92 million shsAverage Volume9.14 million shsMarket Capitalization$4.81 billionAssets Under Management$4.85 billionDividend Yield0.18%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF OverviewSPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More… SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.57%0.57%0.52%0.53%Other Expenses0.00%0.30%0.48%0.56%0.52%Total Expense0.35%0.70%0.72%0.73%0.71%Fee Waiver0.00%-0.45%-0.49%-0.65%-0.54%Net Expense0.35%0.61%0.63%0.58%0.60% Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address XBI ETF News HeadlinesZacks Investment Ideas feature highlights: Alibaba, JD.com, SPDR S&P Biotech ETF, Merck and MicrosoftMay 14 at 2:36 AM | msn.comXBI: Some Tariff Relief Right Now, But Macro Risks Remain In BiotechMay 13 at 6:41 AM | seekingalpha.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.May 14, 2025 | Paradigm Press (Ad)Investors Purchase High Volume of SPDR S&P Biotech ETF Put Options (NYSEARCA:XBI)May 8, 2025 | americanbankingnews.comOptimism is Back for Biotech Stocks. This Time, It Could Last.May 5, 2025 | msn.comSPDR S&P Biotech ETF Experiences Big InflowApril 16, 2025 | nasdaq.comSee More Headlines XBI ETF - Frequently Asked Questions How have XBI shares performed this year? SPDR S&P Biotech ETF's stock was trading at $90.06 on January 1st, 2025. Since then, XBI stock has decreased by 15.2% and is now trading at $76.37. View the best growth stocks for 2025 here. Who are SPDR S&P Biotech ETF's major shareholders? Top institutional investors of SPDR S&P Biotech ETF include Goldman Sachs Group Inc. (21.29%), JPMorgan Chase & Co. (16.32%), Demars Financial Group LLC (4.94%) and Bessemer Group Inc. (2.25%). How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM). Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings151 Fund Statistics Assets Under Management$4.85 billion Average Daily Volume$12.47 million Discount/Premium-0.02% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume52,064 Put Options26,743 Call Options25,321 Short Interest72,740,000 shs Miscellaneous Outstanding Shares63,000,000Beta0.91 Creation Unit50,000 Creation Fee$250.00 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report Top 10 XBI HoldingsExact Sciences (NASDAQ:EXAS)Holding Weight: 3.04%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 2.94%Neurocrine Biosciences (NASDAQ:NBIX)Holding Weight: 2.92%Natera (NASDAQ:NTRA)Holding Weight: 2.88%United Therapeutics (NASDAQ:UTHR)Holding Weight: 2.67%Blueprint Medicines (NASDAQ:BPMC)Holding Weight: 2.44%Insmed (NASDAQ:INSM)Holding Weight: 2.42%Gilead Sciences (NASDAQ:GILD)Holding Weight: 2.41%AbbVie (NYSE:ABBV)Holding Weight: 2.37%Incyte (NASDAQ:INCY)Holding Weight: 2.37%Full Holdings DetailsXBI Sector ExposureXBI Industry Exposure This page (NYSEARCA:XBI) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored“America is running out of power” - The Washington PostAccording to The Washington Post, AI is causing America to “run out of power”... It’s true — utility compan...True Market Insiders | SponsoredTrump Made a Deal. Your Retirement Could Still Be in Danger.America is still barreling toward a financial cliff. This isn't political. It's mathematical. And no trade ...Lear Capital | SponsoredBITCOIN Liquidity pools are the backbone of crypto—and right now, they’re exploding with activity. By providing liqui...Awesomely, LLC | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.